type stringclasses 2
values | gt_table stringlengths 116 12.6k | image imagewidth (px) 109 761 |
|---|---|---|
complex | <table><tr><td> </td><td colspan="2">Standard margin</td><td colspan="2">Reduced margin</td><td> </td><td> </td><td> </td></tr><tr><td>Parameter</td><td>Mean</td><td>St. Dev.</td><td>Mean</td><td>St. Dev.</td><td>Difference (Gy)</td><td>(%)</td><td>p-value</td></tr><tr><td>Max dose (Gy)</td><td>61.4</td><td>1.4</td><td... | |
complex | <table><tr><td></td><td colspan="2">PACCE oxaliplatin cohort [43]</td><td colspan="2">CAIRO2 [47]</td></tr><tr><td></td><td colspan="2"> (<i>N</i> = 823)</td><td colspan="2">(<i>N</i> = 755)</td></tr><tr><td></td><td>Ox + Bev + Pmab</td><td>Ox + Bev</td><td>Cap, Ox + Bev + Cmab</td><td>Cap, Ox + Bev</td></tr><tr><td>Me... | |
complex | <table><tr><td>Name</td><td>Sequence</td><td>Description</td></tr><tr><td><i>NIP5;1_qRT-PCR-1</i></td><td>caccgattttccctctcctgat</td><td rowspan="10">Probes for realtime PCR</td></tr><tr><td><i>NIP5;1_qRT-PCR-2</i></td><td>ctctttcttactctctagcctc</td></tr><tr><td><i>NIP5;1_qRT-PCR-3</i></td><td>gaatgttcccacgaactcgg</td>... | |
simple | <table><tr><td>sCr (mg/dl)</td><td>AKI group</td><td>non-AKI group</td><td><i>P</i> value</td></tr><tr><td></td><td>(<i>n</i> = 11)</td><td>(<i>n</i> = 39)</td><td></td></tr><tr><td>Preoperative</td><td>0.72 ± 0.14</td><td>0.68 ± 0.15</td><td>0.531</td></tr><tr><td>Postoperative</td><td></td><td></td><td></td... | |
complex | <table><tr><td colspan="2">Germplasm or genotypes</td><td>Sites (No)</td><td>Reference</td></tr><tr><td>Type</td><td>Number</td><td></td><td></td></tr><tr><td>Natural accession</td><td>124</td><td>1</td><td>Mengesha et al. (1965)</td></tr><tr><td>Hybrids</td><td>559</td><td>1</td><td>Berhe et al. (1989a,b,c)</td></tr><... | |
complex | <table><tr><td>Variables</td><td>Categories</td><td colspan="8">Asthma confirmed by BHR</td></tr><tr><td></td><td></td><td colspan="4">Crude model</td><td colspan="4">Adjusted model</td></tr><tr><td></td><td></td><td>PR</td><td colspan="2">95 % CI</td><td><i>p</i> value</td><td>PR</td><td colspan="2">95 % CI</td><td><i... | |
simple | <table><tr><td></td><td>ADHD group(<i>n </i>= 16)</td><td>Control group(<i>n </i>= 16)</td><td>Group differences<sup>a</sup></td></tr><tr><td></td><td>M (SD)</td><td>M (SD)</td><td></td></tr><tr><td>Age (years)</td><td>10.7 (1.6)</td><td>10.2 (1.3)</td><td>ns</td></tr><tr><td>IQ (WISC-III)</td><td>97.1 (14.2)</td><td>1... | |
complex | <table><tr><td>Fracture sites</td><td>No. of fractures</td><td>Fracture IR (/1000 PY)</td><td>Age/sex adjusted HR (95 % CI)</td><td>Adjusted HR (95 % CI)</td></tr><tr><td colspan="5">Major osteoporotic fracture</td></tr><tr><td> Never-GLP1-ra use<sup>a</sup></td><td>4373</td><td>6.1</td><td>Reference</td><td>Reference<... | |
complex | <table><tr><td></td><td></td><td></td><td colspan="3">Age</td><td colspan="3">Gender</td></tr><tr><td>EVA derivative</td><td>Intercept</td><td>R<sup>2</sup></td><td>B</td><td>β</td><td>p</td><td>B</td><td>β</td><td><i>p</i></td></tr><tr><td>Prolonged sitting (>30 min)</td><td>−30.6</td><td>.01</td><t... | |
simple | <table><tr><td>Accession no.</td><td>Strain</td><td>BioSample ID</td><td>BioProject ID</td></tr><tr><td>CP018252</td><td>9000</td><td>SAMN05544760</td><td>PRJNA336330</td></tr><tr><td>CP018250</td><td>10671</td><td>SAMN05544761</td><td>PRJNA336330</td></tr><tr><td>CP018247</td><td>7784</td><td>SAMN05544762</td><td>PRJN... | |
simple | <table><tr><td><i>n1</i></td><td><i>n2</i></td><td>Ratio</td><td>Distance</td></tr><tr><td>1</td><td>2</td><td>0.50</td><td>1</td></tr><tr><td>2</td><td>3</td><td>0.67</td><td>1</td></tr><tr><td>3</td><td>4</td><td>0.75</td><td>1</td></tr><tr><td>4</td><td>5</td><td>0.80</td><td>1</td></tr><tr><td>5</td><td>6</td><td>0... | |
complex | <table><tr><td></td><td>Composition</td><td>Strain-to-failure (mm/mm)</td><td>Stress-at-failure (MPa)</td><td>Toughness (MJ/m<sup>3</sup>)</td></tr><tr><td rowspan="4"><i>T</i> = temperature at loss modulus peak</td><td>5% BPA</td><td>1.43 ± 0.0985</td><td>11.9 ± 2.14</td><td>8.99 ± 1.72</td></tr><tr><td... | |
simple | <table><tr><td> </td><td>PR</td><td>GR</td><td>CS</td><td>OD</td><td>IT</td><td>FL</td></tr><tr><td>PR</td><td>—</td><td>MI</td><td>WI</td><td>EI</td><td>SI</td><td>VSI</td></tr><tr><td>GR</td><td></td><td>—</td><td></td><td>SMI</td><td></td><td></td></tr><tr><td>CS</td><td></td><td>WI</td><td>—</td><... | |
complex | <table><tr><td colspan="4">Locus</td><td colspan="5">Initial Signal</td><td colspan="5">Regional Validation Signal</td></tr><tr><td>Chr</td><td>Position (Mb)</td><td>Gene</td><td>Prior HDL or Lipid Association [Ref]</td><td>Lead SNP</td><td>MA</td><td>MAF</td><td>Effect (mg/dl)</td><td><i>P</i>-value</td><td>Lead SNP</... | |
complex | <table><tr><td rowspan="2"></td><td colspan="3">TNF-α Stimulation (U/ml)</td></tr><tr><td>0</td><td>10</td><td>100</td></tr><tr><td>HUVECs in monocultures</td><td>4.9 ± 1.5</td><td>15.7 ± 0.8*</td><td>24.57 ± 3.01**</td></tr><tr><td>HUVECs in direct contact with podocytes</td><td>11.43 ± 4.7</t... | |
complex | <table><tr><td rowspan="2"></td><td>MD</td><td>Normal LV and RV function</td><td>Impaired LV and/or RV function</td><td rowspan="2"><i>p</i> value</td></tr><tr><td><i>N</i> = 63</td><td><i>N</i> = 31</td><td><i>N</i> = 32</td></tr><tr><td>Male, <i>n</i> (%)</td><td>63 (100)</td><td>31 (100)</td><td>32 (100)</td><td>1.0... | |
simple | <table><tr><td>Plasmid</td><td>Description</td><td>Source of reference</td></tr><tr><td>pGK423</td><td>Yeast expression vector containing <i>PGK1</i> promoter, 2 μ origin, <i>HIS3</i> marker, no expression (control plasmid)</td><td>Ishii et al. [10]</td></tr><tr><td>pGK426</td><td>Yeast expression vector containin... | |
simple | <table><tr><td>Source</td><td>Type III sum of squares</td><td>df</td><td>mean square</td><td>F</td><td>P</td></tr><tr><td>population</td><td>33.571</td><td>1</td><td>33.571</td><td>98.623</td><td>< 0.001</td></tr><tr><td>sex</td><td>12.560</td><td>1</td><td>12.560</td><td>36.899</td><td>< 0.001</td></tr><tr><td>p... | |
complex | <table><tr><td>Antibody(ies)</td><td>Number of patients</td><td>Percentage</td></tr><tr><td colspan="3">Alloantibodies</td></tr><tr><td>Anti-c</td><td>10</td><td>6.4</td></tr><tr><td>Anti-C</td><td>3</td><td>1.9</td></tr><tr><td>Anti-c and anti-E</td><td>10</td><td>6.4</td></tr><tr><td>Anti-C + D</td><td>8</td><td>5.1<... | |
simple | <table><tr><td>Genotype</td><td>Strain</td><td>Accession number</td><td>Genotype</td><td>Strain</td><td>Accession number</td></tr><tr><td>GI_1</td><td>NV-USA93</td><td>M87661</td><td>GII_6</td><td>SU3-JPN </td><td>AB039776</td></tr><tr><td>GI_2</td><td>SOV-GBR93</td><td>L07418</td><td>GII_7</td><td>GN273-USA93</td><td>... | |
complex | <table><tr><td>Characteristic</td><td>Bipolar I(<i>n</i> = 1809)</td><td>Bipolar II(<i>n</i> = 922)</td><td>Total(<i>N</i> = 2731)</td></tr><tr><td colspan="4">Gender, <i>n</i> (%)</td></tr><tr><td> Male</td><td>752 (41.6)</td><td>340 (36.9)</td><td>1092 (40.0)</td></tr><tr><td> Female</td><td>1057 (58.4)</td><td>582 (... | |
simple | <table><tr><td> </td><td>0–30 days post-implant</td><td>31–60 days post-implant</td><td>61–90 days post-implant</td></tr><tr><td>Pacemaker</td><td>35%</td><td>30%</td><td>67%</td></tr><tr><td>ICD</td><td>36%</td><td>42%</td><td>66%</td></tr><tr><td>CRT-D</td><td>34%</td><td>32%</td><td>77%</td></tr></... | |
complex | <table><tr><td colspan="3">Categorical variables</td><td colspan="3">Symptoms class of SCIN-total-score</td><td colspan="2">Univariate</td><td colspan="2">Multiple†</td></tr><tr><td colspan="2">GST genotype</td><td>Number (%)</td><td>No (0–5)</td><td>Moderate (6–9)</td><td>Severe (10–18)</td><td... | |
complex | <table><tr><td></td><td colspan="4">Unmatched cohorts</td><td colspan="3">Propensity-score matched cohorts</td></tr><tr><td>Complications</td><td>Human regular insulin <i>n</i> (%) </td><td>Rapid-acting Insulin Analogues <i>n</i> (%) </td><td>Adjusted HR<sup>a</sup> (95% CI)</td><td colspan="2">Human regular insulin <i... | |
complex | <table><tr><td> </td><td colspan="2">Males</td><td colspan="2">Females</td></tr><tr><td> </td><td>AOR</td><td>95% CI</td><td>AOR</td><td>95% CI</td></tr><tr><td>HIV Prevalence</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>≤ 0.37%</td><td>1.0</td><td>-</td><td>1.0</td><td>-</td></tr><tr><td>0.38-0.73%</... | |
simple | <table><tr><td>Species</td><td>Number detected</td><td>(high; medium; low; no visible mould)</td></tr><tr><td><i>Epicoccum nigrum</i></td><td>15</td><td>(7,2,4,2)</td></tr><tr><td><i>Cladosporium cladosporioides</i></td><td>7</td><td>(3,3,1,0)</td></tr><tr><td><i>Aureobasidium pullulan</i></td><td>4</td><td>(1,1,2,0)</... | |
simple | <table><tr><td>Complications</td><td>Survivors (n = 46)</td><td>Non-survivors (n = 29)</td><td>P value<sup>a</sup></td></tr><tr><td>ARDS, n (%)</td><td>17 (37.6)</td><td>25 (86.2)</td><td><.001</td></tr><tr><td>Pneumonia, n (%)</td><td>41 (89.1)</td><td>27 (93.1)</td><td>.866</td></tr><tr><td>Arrhythmia, n (%)</td><... | |
complex | <table><tr><td colspan="2">ROSA item</td><td>Symptom domain</td><td>Factor</td><td>Loading</td></tr><tr><td>1</td><td>The patient is able to remember events from a long time ago.</td><td>Cognition</td><td>Factor 1</td><td>0.6857</td></tr><tr><td>2</td><td>The patient is able to remember events of the recent past.</td><... | |
complex | <table><tr><td></td><td>Hill and Upchurch7</td><td>Alkema <i>et al</i>2</td></tr><tr><td>Type</td><td>Prescriptive</td><td>Descriptive</td></tr><tr><td>Data</td><td>Historical series from four Northwestern European countries (England and Wales, France, the Netherlands and Sweden) and New Zealand, between 1820 and 1964<... | |
complex | <table><tr><td>Domain name and number</td><td>ROC set No.</td><td>ROC variables</td><td>No. Obs</td><td>AUC</td><td>SENS</td><td>SPEC</td><td>PPV</td><td>NPV</td><td>% Risk of rejecting Ho</td><td>ROC <i>P</i> value</td><td>Odds ratio<sup>+</sup></td><td>Odds ratio <i>P</i> value</td><td>Accuracy</td></tr><tr><td rowsp... | |
simple | <table><tr><td>Chemokine</td><td>Forward primer</td><td>Reverse primer</td><td>Product size (bp)</td></tr><tr><td>CCL-chr25s</td><td>5'-TTCTGCTGTTTTTGGTGTTCA</td><td>5'-GCTTTATCCAGTCCTCATCTGG</td><td>216</td></tr><tr><td>CCL-chr24a</td><td>5'-TACTTCTCAGCTTCCTTGTGGAGA</td><td>5'-CTCATCGTCTTCGTCTTCATTGTT</td><td>250</td>... | |
complex | <table><tr><td>Gender</td><td colspan="2">Male</td></tr><tr><td>Age</td><td colspan="2">10 y</td></tr><tr><td>Diagnosis</td><td colspan="2">Oppositional defiant disorder</td></tr><tr><td>Intellligence quotient (IQ)</td><td colspan="2">59</td></tr><tr><td>NCBRF total score</td><td></td><td></td></tr><tr><td> Baseline</t... | |
simple | <table><tr><td></td><td>Screening</td><td>Pretreatment</td><td>Discharge</td><td>End of Intervention</td><td>Follow-up</td></tr><tr><td>Study visits</td><td></td><td>T0</td><td>T1</td><td>T2</td><td>T3</td></tr><tr><td>Written informed consent</td><td>X</td><td></td><td></td><td></td><td></td></tr><tr><td>Screening que... | |
complex | <table><tr><td rowspan="2">Goal</td><td rowspan="2">I have set this goal (<i>N</i>)</td><td rowspan="2">Since joining K-DPP, I have made lifestyle changes to achieve this goal (%)</td><td colspan="3">I will continue to make these changes after the intervention</td></tr><tr><td>Very likely (%)</td><td>Likely (%)</td><td... | |
simple | <table><tr><td>Isoform</td><td>Substrate</td><td>Metabolite</td><td>Ranges of substrate concentrations in the incubations, μM</td><td>Fluorescence detection excitation/emission</td></tr><tr><td>CYP1A</td><td>ER</td><td>resorufin</td><td>0.1–12.0</td><td>560/586 nm</td></tr><tr><td>CYP2A</td><td>coumarin</td>... | |
complex | <table><tr><td>SNPs</td><td>No. of every SNP type</td><td>Caused by</td><td>Total No. of transition and transversion</td></tr><tr><td>A/G</td><td>28769</td><td rowspan="2">Transition</td><td rowspan="2">53208</td></tr><tr><td>C/T</td><td>24439</td></tr><tr><td>A/C</td><td>6832</td><td rowspan="4">Transversion</td><td r... | |
simple | <table><tr><td>Term</td><td>Definition</td></tr><tr><td>SP-trEMBL</td><td>Sequence dataset containing 2,241,227 sequences from the Swiss-Prot (version 48.1) and TrEBML (version 31.1) sequence databases.</td></tr><tr><td>Integr8_263</td><td>Sequence dataset containing 913,094 sequences from 263 completed genomes listed ... | |
simple | <table><tr><td></td><td>EDA group (n = 68)</td><td>Opioid group (n = 98)</td><td>p-value</td></tr><tr><td>Age (years)</td><td>59.3 ± 16.0</td><td>59.9 ± 15.3</td><td>n.s.</td></tr><tr><td>Male gender (%)</td><td>58.8</td><td>66.3</td><td>n.s.</td></tr><tr><td>Hospital stay (days)</td><td>9.8 ± 5.7</td><t... | |
complex | <table><tr><td></td><td colspan="2">PD-L1 Expression</td><td><i>*P</i> value</td></tr><tr><td></td><td>+</td><td>-</td><td></td></tr><tr><td>E-Cadherin</td><td></td><td></td><td></td></tr><tr><td>Down-regulated (≤70 %)</td><td>9 (47)<sup>a</sup></td><td>10 (53)</td><td>0.039</td></tr><tr><td>Positive (> 70 %)<... | |
complex | <table><tr><td>Reference</td><td colspan="2">Numbers studied</td><td>Type of controls</td><td>Susceptibility</td><td>Severity</td><td>Ethnicity</td></tr><tr><td></td><td>Cancer</td><td>Controls</td><td></td><td></td><td></td><td></td></tr><tr><td>Hefler LA et al, 2005 [58]</td><td>269</td><td>227</td><td>Women visiting... | |
complex | <table><tr><td></td><td colspan="4">Region of interest (ROI)</td></tr><tr><td>Period (months)</td><td>1</td><td>2</td><td>3</td><td>4</td></tr><tr><td colspan="5">Monoblock</td></tr><tr><td> 0–12</td><td>–0.16 (–0.22 to –0.10)</td><td>–0.16 (–0.24 to –0.08)</td><td>–0.09 ... | |
complex | <table><tr><td></td><td colspan="2">Group A</td><td colspan="2">Group B</td><td></td></tr><tr><td></td><td colspan="2">6–8 years (<i>n</i> = 11)</td><td colspan="2">9–10 years (<i>n</i> = 17)</td><td rowspan="2"><i>P</i> value</td></tr><tr><td></td><td>median</td><td>range</td><td>median</td><td>range</td><... | |
simple | <table><tr><td>Simulation Results</td><td>Yeast 5</td><td>Yeast 6</td></tr><tr><td>Auxotroph-inducing genes</td><td>92</td><td>93</td></tr><tr><td>Correct auxotrophy predictions</td><td>57</td><td>64</td></tr><tr><td>Mutant incorrectly predicted to be viable in minimal medium</td><td>32</td><td>26</td></tr><tr><td>Muta... | |
complex | <table><tr><td></td><td colspan="3">Group C</td><td colspan="3">Group B</td></tr><tr><td>Subgroups</td><td>Normotensive(<i>n</i> = 41)</td><td>Treated HT(<i>n</i> = 7)</td><td>Untreated HT(<i>n</i> = 7)</td><td>Normotensive(<i>n</i> = 41)</td><td>Treated HT(<i>n</i> = 7)</td><td>Untreated HT(<i>n</i> = 4)</td></tr><tr>... | |
complex | <table><tr><td rowspan="2">Variables</td><td colspan="2">Univariate<sup>a</sup></td><td colspan="2">Multivariate<sup>a</sup></td></tr><tr><td>HR (95 % CI)</td><td><i>P</i> value</td><td>HR (95 % CI)</td><td><i>P</i> value</td></tr><tr><td colspan="5">Baseline characteristics</td></tr><tr><td>Age <70 y (vs. ≥70... | |
simple | <table><tr><td>Subgroups</td><td>n</td><td>Cases of the grade of tracheal intubation conditions (1/2/3/4)</td><td>Cases of the anaphylaxis score (0/1/2/3)</td><td>Duration of surgery (min)</td></tr><tr><td>Group 1</td><td>39</td><td>29/10/0/0</td><td>32/7/0/0</td><td>69 ± 34</td></tr><tr><td>Group 2</td><td>37</td... | |
simple | <table><tr><td>Demographic Characteristics</td><td>TOTAL</td><td>%</td></tr><tr><td>Female</td><td>15</td><td>75%</td></tr><tr><td>Race</td><td></td><td></td></tr><tr><td> White</td><td>15</td><td>75%</td></tr><tr><td> Black</td><td>4</td><td>20%</td></tr><tr><td> Asian</td><td>1</td><td>5%</td></tr><tr><td>Age</td><td... | |
complex | <table><tr><td></td><td></td><td colspan="2">Using allopurinol</td></tr><tr><td>Factor</td><td>Frequency (%)</td><td>No (%)</td><td>Yes (%)</td></tr><tr><td>Age Mean (SD)</td><td>65.6 (12.5)</td><td>65.1 (13.4)</td><td>65.9 (11.6)</td></tr><tr><td>Gender (Male %)</td><td>990 (83.6)</td><td>390 (79.6)</td><td>544 (86.4)... | |
simple | <table><tr><td>MiR</td><td>Parametric p-value</td><td>FDR</td><td>Permutation p-value</td><td>Geom mean of intensities in class 1</td><td>Geom mean of intensities in class 2</td><td>Geom mean of intensities in class 3</td><td>Geom mean of intensities in class 4</td></tr><tr><td>hsa-miR-204-4373094</td><td>0.00004</td><... | |
simple | <table><tr><td>Test</td><td>TAA/TAD (%)</td><td>Control (%)</td><td>P-value</td></tr><tr><td>White Blood Cell</td><td> </td><td> </td><td> </td></tr><tr><td>Normal</td><td>93 (70)</td><td>103 (77)</td><td>0.29</td></tr><tr><td>Low (<3 million cells/mcL)</td><td>8 (6)</td><td>9 (7)</td><td>1</td></tr><tr><td>High (&g... | |
simple | <table><tr><td></td><td>Count</td><td>%</td></tr><tr><td>He/she used to work but is currently unemployed</td><td>0</td><td>0.00</td></tr><tr><td>He/she never worked and neither does now</td><td>0</td><td>0.00</td></tr><tr><td>Clerk (civil or private)</td><td>338</td><td>63.41</td></tr><tr><td>Free professional (tradesm... | |
simple | <table><tr><td>Variables</td><td>N (%)</td><td>Prevalence of Internet use (%)<sup>a</sup></td><td>Total scores<sup>b</sup></td><td>Prevalence of AIA (%)<sup>c,d</sup></td></tr><tr><td>Paternal education (missing 23)</td><td> </td><td><i>p</i> <0.001</td><td><i>p</i> <0.001</td><td><i>p =</i>0.01</td></tr><tr><td>... | |
complex | <table><tr><td rowspan="2"></td><td colspan="3">Mean ± SD before and after treatment with</td></tr><tr><td>PZQ</td><td>ARA</td><td>PZQ + ARA</td></tr><tr><td>Children</td><td>84</td><td>88</td><td>83</td></tr><tr><td colspan="4">Parameter</td></tr><tr><td colspan="4"> PT (seconds)</td></tr><tr><td>Before</td><td>1... | |
complex | <table><tr><td></td><td colspan="2">PLK1</td><td colspan="2">PAK4</td><td colspan="2">PAK5</td><td colspan="2">PAK6</td></tr><tr><td></td><td>SSS</td><td>GAP</td><td>SSS</td><td>GAP</td><td>SSS</td><td>GAP</td><td>SSS</td><td>GAP</td></tr><tr><td>PLK1</td><td>0.000</td><td>100</td><td>0.981</td><td>39.688</td><td>0.976... | |
simple | <table><tr><td> </td><td>Hazard ratio</td><td>95% confidence interval</td><td><i>p</i> value</td></tr><tr><td>Mean age<sup><i>∗</i></sup></td><td>1.026</td><td>1.013–1.040</td><td><0.001</td></tr><tr><td>Country of birth, Nordic country</td><td>1.446</td><td>0.980–2.135</td><td>0.063</td></tr><tr><... | |
simple | <table><tr><td>Cardiometabolic disease outcome</td><td>Amount quintile 1</td><td>Amount quintile 2</td><td>Amount quintile 3</td><td>Amount quintile 4</td><td>Amount quintile 5</td><td><i>P</i>-trend</td></tr><tr><td>Odds ratio (95% CI)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Cardiometab... | |
simple | <table><tr><td>Cluster ID</td><td>No. of sequences</td><td>Percentage of effective siRNAs (%)</td></tr><tr><td>C1</td><td>134</td><td>94</td></tr><tr><td>C2</td><td>150</td><td>70.7</td></tr><tr><td>C3</td><td>125</td><td>70.4</td></tr><tr><td>C4</td><td>147</td><td>61.9</td></tr><tr><td>C5</td><td>141</td><td>43.3</td... | |
simple | <table><tr><td></td><td>No. Patients (%)</td><td>Methylation (%)</td><td><i>P</i></td></tr><tr><td>All patients </td><td>50 (100)</td><td>31( 62)</td><td></td></tr><tr><td> Male</td><td>42 ( 84)</td><td>27 (64)</td><td></td></tr><tr><td> Female</td><td>8 (16)</td><td>4 (50)</td><td>0.450</td></tr><tr><td>Site</td><td><... | |
simple | <table><tr><td>Method</td><td>Resnik</td><td>Relevance</td><td>Wang</td><td>NETSIM</td><td>NETSIM2</td></tr><tr><td>25%</td><td>0.07</td><td>0.15</td><td>0.17</td><td>0.12</td><td>0.002</td></tr><tr><td>50%</td><td>0.17</td><td>0.43</td><td>0.40</td><td>0.47</td><td>1.94</td></tr><tr><td>75%</td><td>0.42</td><td>1.03</... | |
complex | <table><tr><td> </td><td colspan="3">Without DM (n = 334)</td><td colspan="3">With DM (n = 122)</td></tr><tr><td>Characteristics</td><td>VAT T1 (n = 111)</td><td>VAT T2 (n = 112)</td><td>VAT T3 (n = 111)</td><td>VAT T1 (n = 40)</td><td>VAT T2 (n = 41)</td><td>VAT T3 (n = 41)</td></tr><tr><td>Calcified plaque</td><td>1.... | |
simple | <table><tr><td></td><td>Grenoble (n = 232)</td><td>Montpellier (n = 128)</td><td>Paris (n = 272)</td><td>Total (n = 632)</td></tr><tr><td>Genotype, %</td><td></td><td></td><td></td><td></td></tr><tr><td>AA</td><td>16.8</td><td>21.9</td><td>15.4</td><td>17.3</td></tr><tr><td>AG</td><td>47.0</td><td>46.9</td><td>49.6</td... | |
simple | <table><tr><td>Factor</td><td>Score</td></tr><tr><td>Vascular invasion</td><td></td></tr><tr><td> no</td><td>0</td></tr><tr><td> yes</td><td>2.6</td></tr><tr><td>BCLC stage</td><td></td></tr><tr><td> 0-A</td><td>0</td></tr><tr><td> B-C</td><td>1.3</td></tr><tr><td>MiR-145</td><td></td></tr><tr><td> negative</td><td>0</... | |
simple | <table><tr><td></td><td>Exercise Sample</td><td>Physical Activity Sample</td></tr><tr><td>GoF</td><td>.412 [.436]</td><td>.554 [.564]</td></tr><tr><td>APC</td><td>.218; <i>p</i> < .001 [.207; <i>p</i> < .001]</td><td>.291; <i>p</i> < .001 [.252; <i>p</i> <. 001]</td></tr><tr><td>ARS</td><td>.195; <i>p</i> =... | |
simple | <table><tr><td>Time for data collection</td><td>Participants in the interviews</td></tr><tr><td>May–September 2013</td><td>Unit managers, n = 20Regional coordinators, n = 4Officials, n = 24</td></tr><tr><td>May–September 2014</td><td>Unit managers, n = 5Officials, n = 16</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.